Physician profile
Jeffrey Capati
NPI 1083034870
$3,235.44
in general payments reported to CMS, 2019-2025
13 companies · $554 in 2025
The $554 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,522 · 2020: $138 · 2021: $109 · 2022: $212 · 2023: $327 · 2024: $374 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,362.98 | 2019-2025 | Spyglass, Spyglass, Advanix Biliary |
| Abbvie INC. | $1,166.53 | 2019-2025 | Rinvoq, Mavyret |
| Janssen Biotech, INC. | $300.27 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $101.12 | 2024 | |
| Steris Corporation | $95.74 | 2019 | |
| Janssen Scientific Affairs, LLC | $86.07 | 2019 | |
| Intercept Pharmaceuticals, INC. | $34.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.14 | 2020 | |
| Shionogi INC | $17.11 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.24 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.06 | 2019 | |
| Gilead Sciences, INC. | $12.26 | 2019 | |
| Covidien LP | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Capati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.